Recent Finacing
Recent Raise
Biomea Fusion develops a platform of irreversible inhibitors targeting genomically defined oncogenic drivers across hematologic and solid tumors, advancing an irreversible menin-MLL PPI inhibitor through IND-enabling studies toward clinical entry.
